Investor Relations

Company Profile

Axcan is a privately-held, leading multinational specialty pharmaceutical company focused on gastroenterology. The Company develops and markets a broad line of prescription products to treat a range of gastrointestinal diseases and disorders such as inflammatory bowel disease, irritable bowel syndrome, cholestatic liver diseases and complications related to pancreatic insufficiency. Axcan's products are marketed by its own specialized sales forces in North America and the European Union and through commercial collaborations in many markets around the world.

Latest News

April 28, 2008
Axcan Provides Preliminary Revenue Results for the Second Quarter of Fiscal Year 2008


February 25, 2008
Axcan Announces Completion of Transaction With TPG Capital


February 13, 2008
Axcan and TPG Capital Receive Investment Canada Act Approval in Connection With Proposed Acquisition

 

 

 

 



Home  |  Corporate Profile  |  Investor Relations  |  Events & Webcasts
Conferences  |  Products & Services  |  Export Operations  |  Axcan Worldwide






IR and Communications Contact
Isabelle Adjahi
Senior Director,
Investor Relations and Communications
Axcan Pharma Inc.
597, Laurier Blvd.
Mont-Saint-Hilaire
QC J3H 6C4
Canada
Tel : (450) 467-2600
or
1 (877) 982-2600 ext. 2000
Fax: (450) 464-9979
iadjahi@axcan.com